Free tool
FAERS Monitor: Potassium Phosphates
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212121 or its brand name (Potassium Phosphates, Potassium Phosphate, Dibasic, Potassium Phosphate, Monobasic). Reports on generic versions are filed under their own applications.
Reports
886
Serious
765
86% of reports
Hospitalization
525
Death reported
174
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea64
- nausea62
- pyrexia61
- pneumonia59
- cytokine release syndrome52
- off label use52
- vomiting49
- hypotension47
- dyspnoea44
- acute kidney injury42
- fatigue42
- febrile neutropenia42
- sepsis40
- toxic epidermal necrolysis33
- anaemia31
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 18 |
| 2005 | 11 |
| 2006 | 23 |
| 2007 | 21 |
| 2008 | 12 |
| 2009 | 31 |
| 2010 | 28 |
| 2011 | 37 |
| 2012 | 37 |
| 2013 | 27 |
| 2014 | 36 |
| 2015 | 46 |
| 2016 | 45 |
| 2017 | 31 |
| 2018 | 32 |
| 2019 | 47 |
| 2020 | 76 |
| 2021 | 79 |
| 2022 | 75 |
| 2023 | 62 |
| 2024 | 34 |
| 2025 | 40 |
| 2026 | 38 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,273 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cytokine release syndromeSignal | 52 | 61.7 | 47.4 | 3,040 |
| toxic epidermal necrolysisSignal | 33 | 51.7 | 37.0 | 1,588 |
| febrile neutropeniaSignal | 42 | 15.0 | 11.2 | 538 |
| sepsisSignal | 40 | 8.5 | 6.3 | 259 |
| acute kidney injurySignal | 42 | 6.5 | 4.9 | 192 |
| hypotensionSignal | 47 | 5.6 | 4.2 | 173 |
| pneumoniaSignal | 59 | 4.3 | 3.4 | 150 |
| pyrexiaSignal | 61 | 4.2 | 3.3 | 147 |
| anaemiaSignal | 31 | 3.9 | 2.7 | 63 |
| vomitingSignal | 49 | 2.5 | 1.9 | 43 |
| diarrhoeaSignal | 64 | 2.4 | 1.9 | 50 |
| nausea | 62 | 1.9 | 1.5 | 25 |
| dyspnoea | 44 | 1.8 | 1.4 | 17 |
| off label use | 52 | 1.4 | 1.1 | 6 |
| fatigue | 42 | 1.3 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.